Regencell Bioscience Lim... (RGC)
NASDAQ: RGC
· Real-Time Price · USD
12.95
0.25 (1.97%)
At close: Aug 15, 2025, 3:11 PM
Regencell Bioscience Income Statement
Financials in USD. Fiscal
year is
July - June.
| Fiscal Year | Q2 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Dec 31, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 |
Revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | -2.34B | n/a | n/a | n/a | -2.34B | n/a | n/a | n/a |
Cost of Revenue | n/a | n/a | n/a | n/a | n/a | 769.69K | n/a | n/a | n/a | 604.4K | n/a | n/a | n/a | 877.7M | n/a | n/a | n/a |
Gross Profit | n/a | n/a | n/a | n/a | n/a | -769.69K | n/a | n/a | n/a | -2.34B | n/a | n/a | n/a | -3.22B | n/a | n/a | n/a |
Operating Income | -1.98M | -2.42M | -1.21K | -1.16K | -1.16K | -2.84M | -1.42K | -3.43M | -1.71K | -3.96M | -1.98K | -3.66M | -1.83K | -506.45 | -506.45 | -184.23 | -184.23 |
Interest Income | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Pretax Income | -1.85M | -2.18M | -1.09K | -1.09K | -1.09K | -2.75M | -1.37K | -3.32M | -1.66K | -3.94M | -1.97K | -3.66M | -1.83K | -506.45 | -506.45 | -166.92 | -166.92 |
Net Income | -1.85M | -2.24M | -1.12K | -1.03K | -1.03K | -2.64M | -1.32K | -3.23M | -1.61K | -3.94M | -1.93K | -3.66M | -1.8K | -506.45 | -506.45 | -166.92 | -166.92 |
Selling & General & Admin | 1.47M | 1.84M | 977.56 | 913.55 | 913.55 | 1.84M | 1.36K | 2.08M | 1.04K | 1.96M | 1.3K | 2.54M | 1.27K | 414.05 | 414.05 | 57.47 | 57.47 |
Research & Development | 507.38K | 581.48K | 290.74 | 242.38 | 242.38 | 231.46K | 115.73 | 1.35M | 675.09 | 1.4M | 698.38 | 1.12M | 557.70 | 92.40 | 92.40 | 126.76 | 126.76 |
Other Expenses | n/a | n/a | -55.87 | 0.00 | 0.00 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | -285.7M | n/a | n/a | n/a |
Operating Expenses | 1.98M | 2.42M | 1.21K | 1.16K | 1.16K | 2.07M | 1.37K | 3.43M | 1.66K | 3.35M | 1.97K | 3.66M | 1.83K | 506.45 | 506.45 | 166.92 | 166.92 |
Interest Expense | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Selling & Marketing Expenses | n/a | 14.18 | 14.18 | 48.53 | 48.53 | 82.28 | 82.28 | 49.05 | 49.05 | 8.61 | 8.61 | 4.02 | 4.02 | 0.79 | 0.79 | n/a | n/a |
Cost & Expenses | 1.98M | 2.42M | 1.21K | 1.16K | 1.16K | 2.84M | 1.37K | 3.43M | 1.66K | 3.96M | 1.97K | 3.66M | 1.83K | 506.45 | 506.45 | 166.92 | 166.92 |
Income Tax Expense | n/a | n/a | n/a | -119.27K | -59.64 | n/a | -51.67 | n/a | -43.93 | -40.62 | -40.62 | -6.61 | -33.68 | -70.9M | n/a | n/a | n/a |
Shares Outstanding (Basic) | 13.01M | 494.49M | 494.49M | 494.49M | 494.49M | 494.49M | 494.46M | 494.49M | 494.46M | 494.49M | 494.8M | 492.75M | 478.38M | 380M | 380M | 380M | 380M |
Shares Outstanding (Diluted) | 13.01M | 494.49M | 494.47M | 494.46M | 494.46M | 494.49M | 494.46M | 494.49M | 494.46M | 494.49M | 494.8M | 492.75M | 478.38M | 380M | 380M | 380M | 380M |
EPS (Basic) | -0.14 | -0.00 | -0.00 | -0.00 | -0.00 | -0.01 | -0.00 | -0.01 | -0.00 | -0.01 | -0.00 | -0.01 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 |
EPS (Diluted) | -0.14 | -0.00 | -0.00 | -0.00 | -0.00 | -0.01 | -0.00 | -0.01 | -0.00 | -0.01 | -0.00 | -0.01 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 |
EBITDA | -1.85M | -2.18M | -1.14K | -2.19M | -1.08M | -1.98M | -1.38M | -3.43M | -1.68M | -3.33M | -1.97M | -3.66M | -1.82M | -499.89K | -499.89K | -177.56K | -177.56K |
EBIT | -1.85M | -2.18M | -1.21K | -1.16M | -1.16M | -2.75M | -1.42M | -3.32M | -1.71M | -3.94M | -1.98M | -3.66M | -1.83M | -506.45K | -506.45K | -184.23K | -184.23K |
Depreciation & Amortization | n/a | 247.54K | 73.28 | 73.28 | 73.28 | 769.69K | 37.54 | 37.54 | 37.54 | 604.4K | 6.61 | 6.61 | 6.61 | 6.56 | 6.56 | 6.67 | 6.67 |